To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Already have an account?
Caprion Proteomics and Applied Biosystems Work Together to Accelerate Protein Biomarker Verification and Validation
Read time: Less than a minute
Caprion Proteomics Inc.
has announced that it is working with
Applied Biosystems
, a division of Life Technologies Corporation, to accelerate the verification and validation of protein biomarker candidates toward potential use in clinical settings.
Caprion is extending its leadership in mass spectrometry-based biomarker services, by applying QTRAP technology for the development and deployment of multiple reaction monitoring (MRM) assays to advance the clinical validation of biomarker candidates. Caprion will discuss this scientific initiative at the Biomarker World Congress 2009 conference in Philadelphia.
Discovery of a significant number of biomarker candidates in academia and industry has created the need to verify and validate these markers in large-scale projects, to determine the most promising for clinical development. Caprion specializes in large-scale studies of biomarkers as a service for pharmaceutical and biotechnology companies, as well as for government agencies. Applied Biosystems provides mass spectrometry technology that complements Caprion’s long-standing strength in biomarker discovery, to address the need to advance candidates along the biomarker continuum.
QTRAP technology, which was developed by the Applied Biosystems/MDS Analytical Technologies joint venture, enables integrated quantitative and qualitative analysis through the MIDAS workflow, for MRM assay development and quantitative results. This makes it the technology of choice for Caprion to expand its quantitative capabilities into this rapidly emerging field.
Caprion is extending its leadership in mass spectrometry-based biomarker services, by applying QTRAP technology for the development and deployment of multiple reaction monitoring (MRM) assays to advance the clinical validation of biomarker candidates. Caprion will discuss this scientific initiative at the Biomarker World Congress 2009 conference in Philadelphia.
Discovery of a significant number of biomarker candidates in academia and industry has created the need to verify and validate these markers in large-scale projects, to determine the most promising for clinical development. Caprion specializes in large-scale studies of biomarkers as a service for pharmaceutical and biotechnology companies, as well as for government agencies. Applied Biosystems provides mass spectrometry technology that complements Caprion’s long-standing strength in biomarker discovery, to address the need to advance candidates along the biomarker continuum.
QTRAP technology, which was developed by the Applied Biosystems/MDS Analytical Technologies joint venture, enables integrated quantitative and qualitative analysis through the MIDAS workflow, for MRM assay development and quantitative results. This makes it the technology of choice for Caprion to expand its quantitative capabilities into this rapidly emerging field.
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
